Predicting final product properties of melt extruded solid dispersions from process parameters using Raman spectrometry

Tamás Vigh, Gábor Drávavölgyi, Péter L. Sóti, Hajnalka Pataki, Tamás Igricz, István Wagner, Balázs Vajna, J. Madarász, G. Marosi, Zsombor K. Nagy

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Raman spectrometry was utilized to estimate degraded drug percentage, residual drug crystallinity and glass-transition temperature in the case of melt-extruded pharmaceutical products. Tight correlation was shown between the results obtained by confocal Raman mapping and transmission Raman spectrometry, a PAT-compatible potential in-line analytical tool. Immediate-release spironolactone-Eudragit E solid dispersions were the model system, owing to the achievable amorphization and the heat-sensitivity of the drug compound. The deep investigation of the relationship between process parameters, residual drug crystallinity and degradation was performed using statistical tools and a factorial experimental design defining 54 different circumstances for the preparation of solid dispersions. From the examined factors, drug content (10, 20 and 30%), temperature (110, 130 and 150. °C) and residence time (2.75, 11.00 and 24.75. min) were found to have significant and considerable effect. By forming physically stable homogeneous dispersions, the originally very slow dissolution of the lipophilic and poorly water-soluble spironolactone was reasonably improved, making 3. minute release possible in acidic medium.

Original languageEnglish
Pages (from-to)166-177
Number of pages12
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume98
DOIs
Publication statusPublished - 2014

Fingerprint

Dispersions
Spectrometry
Spectrum Analysis
Pharmaceutical Preparations
Spironolactone
Transition Temperature
Amorphization
Design of experiments
Glass
Dissolution
Research Design
Hot Temperature
Degradation
Temperature
Water

Keywords

  • Amorphization
  • Degradation
  • Melt extrusion
  • Solid dispersion
  • Transmission raman spectrometry

ASJC Scopus subject areas

  • Analytical Chemistry
  • Drug Discovery
  • Pharmaceutical Science
  • Spectroscopy
  • Clinical Biochemistry
  • Medicine(all)

Cite this

Predicting final product properties of melt extruded solid dispersions from process parameters using Raman spectrometry. / Vigh, Tamás; Drávavölgyi, Gábor; Sóti, Péter L.; Pataki, Hajnalka; Igricz, Tamás; Wagner, István; Vajna, Balázs; Madarász, J.; Marosi, G.; Nagy, Zsombor K.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 98, 2014, p. 166-177.

Research output: Contribution to journalArticle

Vigh, Tamás ; Drávavölgyi, Gábor ; Sóti, Péter L. ; Pataki, Hajnalka ; Igricz, Tamás ; Wagner, István ; Vajna, Balázs ; Madarász, J. ; Marosi, G. ; Nagy, Zsombor K. / Predicting final product properties of melt extruded solid dispersions from process parameters using Raman spectrometry. In: Journal of Pharmaceutical and Biomedical Analysis. 2014 ; Vol. 98. pp. 166-177.
@article{eae1e4b9121d49f1b596c52c5781d4a7,
title = "Predicting final product properties of melt extruded solid dispersions from process parameters using Raman spectrometry",
abstract = "Raman spectrometry was utilized to estimate degraded drug percentage, residual drug crystallinity and glass-transition temperature in the case of melt-extruded pharmaceutical products. Tight correlation was shown between the results obtained by confocal Raman mapping and transmission Raman spectrometry, a PAT-compatible potential in-line analytical tool. Immediate-release spironolactone-Eudragit E solid dispersions were the model system, owing to the achievable amorphization and the heat-sensitivity of the drug compound. The deep investigation of the relationship between process parameters, residual drug crystallinity and degradation was performed using statistical tools and a factorial experimental design defining 54 different circumstances for the preparation of solid dispersions. From the examined factors, drug content (10, 20 and 30{\%}), temperature (110, 130 and 150. °C) and residence time (2.75, 11.00 and 24.75. min) were found to have significant and considerable effect. By forming physically stable homogeneous dispersions, the originally very slow dissolution of the lipophilic and poorly water-soluble spironolactone was reasonably improved, making 3. minute release possible in acidic medium.",
keywords = "Amorphization, Degradation, Melt extrusion, Solid dispersion, Transmission raman spectrometry",
author = "Tam{\'a}s Vigh and G{\'a}bor Dr{\'a}vav{\"o}lgyi and S{\'o}ti, {P{\'e}ter L.} and Hajnalka Pataki and Tam{\'a}s Igricz and Istv{\'a}n Wagner and Bal{\'a}zs Vajna and J. Madar{\'a}sz and G. Marosi and Nagy, {Zsombor K.}",
year = "2014",
doi = "10.1016/j.jpba.2014.05.025",
language = "English",
volume = "98",
pages = "166--177",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

TY - JOUR

T1 - Predicting final product properties of melt extruded solid dispersions from process parameters using Raman spectrometry

AU - Vigh, Tamás

AU - Drávavölgyi, Gábor

AU - Sóti, Péter L.

AU - Pataki, Hajnalka

AU - Igricz, Tamás

AU - Wagner, István

AU - Vajna, Balázs

AU - Madarász, J.

AU - Marosi, G.

AU - Nagy, Zsombor K.

PY - 2014

Y1 - 2014

N2 - Raman spectrometry was utilized to estimate degraded drug percentage, residual drug crystallinity and glass-transition temperature in the case of melt-extruded pharmaceutical products. Tight correlation was shown between the results obtained by confocal Raman mapping and transmission Raman spectrometry, a PAT-compatible potential in-line analytical tool. Immediate-release spironolactone-Eudragit E solid dispersions were the model system, owing to the achievable amorphization and the heat-sensitivity of the drug compound. The deep investigation of the relationship between process parameters, residual drug crystallinity and degradation was performed using statistical tools and a factorial experimental design defining 54 different circumstances for the preparation of solid dispersions. From the examined factors, drug content (10, 20 and 30%), temperature (110, 130 and 150. °C) and residence time (2.75, 11.00 and 24.75. min) were found to have significant and considerable effect. By forming physically stable homogeneous dispersions, the originally very slow dissolution of the lipophilic and poorly water-soluble spironolactone was reasonably improved, making 3. minute release possible in acidic medium.

AB - Raman spectrometry was utilized to estimate degraded drug percentage, residual drug crystallinity and glass-transition temperature in the case of melt-extruded pharmaceutical products. Tight correlation was shown between the results obtained by confocal Raman mapping and transmission Raman spectrometry, a PAT-compatible potential in-line analytical tool. Immediate-release spironolactone-Eudragit E solid dispersions were the model system, owing to the achievable amorphization and the heat-sensitivity of the drug compound. The deep investigation of the relationship between process parameters, residual drug crystallinity and degradation was performed using statistical tools and a factorial experimental design defining 54 different circumstances for the preparation of solid dispersions. From the examined factors, drug content (10, 20 and 30%), temperature (110, 130 and 150. °C) and residence time (2.75, 11.00 and 24.75. min) were found to have significant and considerable effect. By forming physically stable homogeneous dispersions, the originally very slow dissolution of the lipophilic and poorly water-soluble spironolactone was reasonably improved, making 3. minute release possible in acidic medium.

KW - Amorphization

KW - Degradation

KW - Melt extrusion

KW - Solid dispersion

KW - Transmission raman spectrometry

UR - http://www.scopus.com/inward/record.url?scp=84902343401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902343401&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2014.05.025

DO - 10.1016/j.jpba.2014.05.025

M3 - Article

C2 - 24929869

AN - SCOPUS:84902343401

VL - 98

SP - 166

EP - 177

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

ER -